author-photo

Inderjit Mehmi

NorthShore University HealthSystem

32

Papers

1097

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

Abstract PS9-59: Pooled efficacy analysis from two phase 3 studies in patients receiving eflapegrastim, a novel, long-acting granulocyte-colony stimulating factor, following TC for early-stage breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Longitudinal Vaccine-Induced Humoral Immune Response in Cancer Patients

2021
Show All
- Source
- Cite
- Save
Citations (0)
Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P2-14-12: Eflapegrastim, a novel long-acting granulocyte-colony stimulating factor: Integrated safety results in patients with early-stage breast cancer treated with TC chemotherapy

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.

2020 International Journal of Molecular Sciences
Show All
- Source
- Cite
- Save
Citations (7)
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (5)
Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)